Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Testicular Cancer

Double dose-intensive chemotherapy with autologous stem cell support for relapsed and refractory testicular cancer: the University of Michigan experience and literature review

Abstract

Testicular cancer patients refractory or in relapse after primary chemotherapy have 25% 5-year progression-free survival with salvage. To improve prognosis, patients entered a phase I/II tandem dose-escalation trial of carboplatin (1500–2100 mg/m2) and etoposide (1200–2250 mg/m2) with ABMT. Patients were eligible for a second cycle if disease progression was absent and performance status allowed. From August 1990 to June 1998, 29 males (25 NSGCT) were treated. At the time of ABMT, 10 were chemosensitive, four were chemoresistant, and 10 were absolutely refractory to platinum. Disease status (no. patients) at transplant: primary refractory disease (six), first relapse (10), second relapse (eight), third relapse (five). Fifteen (52%) received both transplants. Treatment-related mortality was 10%. Best response after ABMT included: two CR, one CR surgically NED, five PR, three PR surgically NED, seven SD, and eight PD. Eight (28%) patients are continuously progression-free a median 60 months (range, 31–93) from first ABMT. Three seminoma patients remain progression-free. Of five long-term NSGCT survivors, four were treated in first relapse with platinum-sensitive disease. Eighteen relapses occurred a median of 4 months after ABMT I (two late relapses at 28 and 44 months). The median PFS and OS for the whole group are 4 and 14 months, respectively. Patients with relapsed/ refractory testicular cancer benefit most from ABMT if they have platinum-sensitive disease in first relapse. Patients who do poorly despite ABMT have a mediastinal primary site, true cisplatin-refractory disease, disease progression prior to ABMT, and/or markedly elevated βHCG at ABMT. New treatment modalities are needed for the latter group. Bone Marrow Transplantation (2001) 27, 939–947.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Bosl GJ, Motzer RJ . Testicular germ-cell cancer New Engl J Med 1997 337: 242–253

    Article  CAS  Google Scholar 

  2. Parker SL, Tong T, Bolden S, Wingo PA . Cancer statistics, 1997 CA 1997 47: 5–27

    CAS  PubMed  Google Scholar 

  3. Loehrer PJ, Lauer R, Roth BJ et al. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide Ann Int Med 1988 109: 540–546

    Article  Google Scholar 

  4. Harstrick A, Schmoll H-J, Wilke H et al. Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma J Clin Oncol 1991 9: 1549–1555

    Article  CAS  Google Scholar 

  5. McCaffrey JA, Mazumdar M, Bajorin DF et al. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival J Clin Oncol 1997 15: 2559–2563

    Article  CAS  Google Scholar 

  6. Loehrer PJ, Gonin R, Nichols CR et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor J Clin Oncol 1998 16: 2500–2504

    Article  CAS  Google Scholar 

  7. Birch R, Williams SD, Cone A et al. Prognostic factors for favorable outcome in disseminated germ cell tumors J Clin Oncol 1986 4: 400–407

    Article  CAS  Google Scholar 

  8. Einhorn LH . Treatment of testicular cancer: a new and improved model (Karnofsky Memorial Lecture) J Clin Oncol 1990 8: 1777–1781

    Article  CAS  Google Scholar 

  9. Bosl GJ, Geller NL, Cirrincione C et al. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer Cancer Res 1983 43: 3403–3407

    CAS  PubMed  Google Scholar 

  10. Mead GM, Stenning SP, Parkinson MC et al. The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors J Clin Oncol 1992 10: 85–94

    Article  CAS  Google Scholar 

  11. International Germ Cell Cancer Collaborative Group . International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers J Clin Oncol 1997 15: 594–603

    Article  Google Scholar 

  12. Williams SD, Birch R, Einhorn LH et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide New Engl J Med 1987 316: 1435–1440

    Article  CAS  Google Scholar 

  13. Bosl GJ, Geller NL, Bajorin D et al. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good prognosis germ cell tumors J Clin Oncol 1988 6: 1231–1238

    Article  CAS  Google Scholar 

  14. Einhorn LH, Williams SD, Loehrer PJ et al. Evaluation of optimal duration of chemotherapy in favorable prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol J Clin Oncol 1989 7: 387–391

    Article  CAS  Google Scholar 

  15. Wozniak AJ, Samson MK, Shah NT et al. A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group Study J Clin Oncol 1991 9: 70–76

    Article  CAS  Google Scholar 

  16. Bajorin DF, Sarosdy MF, Pfister DG et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good risk germ cell tumors: a multiinstitutional study J Clin Oncol 1993 11: 598–606

    Article  CAS  Google Scholar 

  17. Levi JA, Raghavan D, Harvey V et al. The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinomas J Clin Oncol 1993 11: 1300–1305

    Article  CAS  Google Scholar 

  18. Loehrer PJ, Johnson D, Elson P et al. Importance of bleomycin in favorable-prognosis germ cell tumors: an Eastern Cooperative Oncology Group trial J Clin Oncol 1995 13: 470–476

    Article  Google Scholar 

  19. De Wit R, Stoter G, Kaye SB et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group J Clin Oncol 1997 15: 1837–1843

    Article  CAS  Google Scholar 

  20. Horwich A, Sleijfer DT, Fossa SD et al. Randomized trial of bleomycin, etoposide and cisplatin compared with bleomycin, etoposide and carboplatin in good prognosis metastatic nonseminomatous germ cell cancer: a multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial J Clin Oncol 1997 15: 1844–1852

    Article  CAS  Google Scholar 

  21. Saxman SB, Finch D, Gonin R, Einhorn LH . Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide and cisplatin in favorable-prognosis germ cell tumors: the Indiana University Experience J Clin Oncol 1998 16: 702–706

    Article  CAS  Google Scholar 

  22. Nichols CR, Tricot G, Williams SD et al. Dose-intensive chemotherapy in refractory germ cell cancer – a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation J Clin Oncol 1989 7: 932–939

    Article  CAS  Google Scholar 

  23. Adams PT, Ayash L, Ratanatharathorn V et al. Phase I/II high-dose chemotherapy with autologous stem cell support for testis cancer: the University of Michigan experience Proc Am Soc Clin Oncol 1998 17: 325a (Abstr. 1252)

    Google Scholar 

  24. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457–481

    Article  Google Scholar 

  25. Armitage P, Berry G . Statistical Methods in Medical Research (2nd edn) Blackwell Scientific: Oxford 1987

    Google Scholar 

  26. Fleming ID, Cooper JS, Henson DE et al (eds). AJCC Cancer Staging Handbook Lippincott-Raven: Philadelphia, PA 1998

    Google Scholar 

  27. Skipper HE . Combination therapy: some concepts and results Cancer Chemother Rep 1974 4: 137–145

    CAS  Google Scholar 

  28. Frei E, Cucchi C, Rosowsky A et al. Alkylating agent resistance: in vitro studies of human cell lines Proc Natl Acad Sci USA 1985 82: 2158–2162

    Article  CAS  Google Scholar 

  29. Teicher B, Cucchi C, Lee J et al. Alkylating agents: in vitro studies of cross-resistance patterns in human tumor cell lines Cancer Res 1986 46: 4379–4383

    CAS  PubMed  Google Scholar 

  30. Schabel F . Patterns of resistance and therapeutic synergism among alkylating agents Fund Cancer Chemother 1978 23: 200–215

    CAS  Google Scholar 

  31. Schabel F, Griswold D, Corbett T . Increasing therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology Cancer 1984 54 (Suppl. 6): 1160–1167

    Article  Google Scholar 

  32. Holden SA, Teicher B, Ayash LJ et al. A preclinical model for sequential high-dose chemotherapy Cancer Chemother Pharmacol 1995 36: 61–64

    Article  CAS  Google Scholar 

  33. Nichols CR, Tricot PJ, Williams SD et al. Dose-intensive chemotherapy in refractory germ cell cancer – a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation J Clin Oncol 1989 7: 932–939

    Article  CAS  Google Scholar 

  34. Nichols CR, Andersen J, Lazarus HM et al. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol J Clin Oncol 1992 10: 558–563

    Article  CAS  Google Scholar 

  35. Broun ER, Nichols CR, Kneebone P et al. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue Ann Int Med 1992 117: 124–128

    Article  CAS  Google Scholar 

  36. Broun ER, Nichols CR, Turns M et al. Early salvage therapy for germ cell cancer using high-dose chemotherapy with autologous bone marrow support Cancer 1994 73: 1716–1720

    Article  CAS  Google Scholar 

  37. Broun ER, Nichols CR, Gize G et al. Tandem high-dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer Cancer 1997 79: 1605–1610

    Article  CAS  Google Scholar 

  38. Motzer RJ, Bosl GJ . High-dose chemotherapy for resistant germ cell tumors: recent advances and future directions J Natl Cancer Inst 1992 84: 1703–1709

    Article  CAS  Google Scholar 

  39. Motzer RJ, Gulati SC, Crown JP et al. High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors Cancer 1992 69: 550–556

    Article  CAS  Google Scholar 

  40. Motzer RJ, Mazumdar M, Bosl GJ et al. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity J Clin Oncol 1996 14: 1098–1105

    Article  CAS  Google Scholar 

  41. Lotz JP, Machover D, Malassagne B et al. Phase I–II study of two consecutive courses of high-dose epipodophyllotoxic, ifosfamide, and carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumors J Clin Oncol 1991 9: 1860–1870

    Article  CAS  Google Scholar 

  42. Beyer J, Kramar A, Mandanas R et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables J Clin Oncol 1996 14: 2638–2645

    Article  CAS  Google Scholar 

  43. Rodenhuis S, van der Wall E, ten Bokkel Huinink WW et al. Pilot study of a high-dose carboplatin-based salvage strategy for relapsing or refractory germ cell cancer Cancer Invest 1995 13: 355–362

    Article  CAS  Google Scholar 

  44. Droz JP, Pico JL, Ghosn M et al. Long-term survivors after salvage high-dose chemotherapy with bone marrow rescue in refractory germ cell cancer Eur J Cancer 1991 27: 831–835

    Article  CAS  Google Scholar 

  45. Siegert W, Beyer J, Strohscheer I et al. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study J Clin Oncol 1994 12: 1223–1231

    Article  CAS  Google Scholar 

  46. Lotz JP, Andre T, Donsimoni R et al. High-dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults Cancer 1995 75: 874–885

    Article  CAS  Google Scholar 

  47. Margolin K, Doroshow JH, Ahn C et al. Treatment with germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem cell support J Clin Oncol 1996 14: 2631–2637

    Article  CAS  Google Scholar 

  48. Broun ER, Nichols CR, Tricot PJ et al. High-dose carboplatin/VP-16 plus ifosfamide with autologous bone marrow support in the treatment of refractory germ cell tumors Bone Marrow Transplant 1991 7: 53–56

    CAS  PubMed  Google Scholar 

  49. Bhatia S, Cornetta K, Broun ER et al. High-dose chemotherapy with peripheral stem cell or autologous bone marrow transplant as initial salvage chemotherapy for testicular cancer Proc Am Soc Clin Oncol 1998 17: 321a (Abstr. 1239)

    Google Scholar 

  50. Barnett MJ, Coppin CML, Murray N et al. High-dose chemotherapy and autologous bone marrow transplantation for patients with poor prognosis nonseminomatous germ cell tumors Br J Cancer 1993 68: 594–598

    Article  CAS  Google Scholar 

  51. Motzer RJ, Mazumdar M, Bajorin DF et al. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors J Clin Oncol 1997 15: 2546–2552

    Article  CAS  Google Scholar 

  52. Matthay KK, Villablanca JG, Seeger RC et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid New Engl J Med 1999 341: 1165–1173

    Article  CAS  Google Scholar 

  53. Iida K, Kawai K, Hayashi H et al. Cases of refractory testicular cancer treated with all-trans-retinoic acid Jap J Cancer Chemother 1999 26: 841–844

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ayash, L., Clarke, M., Silver, S. et al. Double dose-intensive chemotherapy with autologous stem cell support for relapsed and refractory testicular cancer: the University of Michigan experience and literature review. Bone Marrow Transplant 27, 939–947 (2001). https://doi.org/10.1038/sj.bmt.1703008

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703008

Keywords

This article is cited by

Search

Quick links